Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Good Manufacturing Practices Production of Human Placental Derived Mesenchymal Stem Cells for Therapeutic Applications: Focus on Multiple Sclerosis Publisher Pubmed



Shokati A1, 2, 3 ; Naser Moghadasi A2 ; Ghashghaei A3 ; Sahraian MA2 ; Chahardouli B3 ; Mousavi SA3 ; Ai J3 ; Nikbakht M3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran
  3. 3. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Kargar Shomali Street, Tehran, Iran

Source: Molecular Biology Reports Published:2024


Abstract

Background: Among neurological diseases, multiple sclerosis (MS) affects mostly young adults and can cause long-term disability. While most medications with approval from regulatory agencies are very effective in treating MS disease, they are unable to repair the tissue damage found in the central nervous system (CNS). Consequently, Cell-based therapy particularly using mesenchymal stem/stromal cells (MSCs), holds promise for neuroprotection and tissue repair in MS treatment. Furthermore, placenta-derived MSCs (PLMSCs) have shown the potential to treat MS due to their abundance, noninvasive isolation from discarded tissues, no ethical problems, anti-inflammatory, and reparative properties. Accordingly, good manufacturing practices (GMPs) plays a crucial part in clinical SCs manufacturing. The purpose of our article is to discuss GMP-grade PLMSC protocols for treating MS as well as other clinical applications. Methods and results: Placental tissue obtained of a healthy donor during the caesarean delivery and PLMSCs isolated by GMP standards. Flow cytometry was used to assess the expression of the CD markers CD34, CD105, CD90, and CD73 in the MSCs and the mesodermal differentiation ability was evaluated. Furthermore, Genetic evaluation of PLMSCs was done by G-banded karyotyping and revealed no chromosomal instability. In spite of the anatomical origin of the starting material, PLMSCs using this method of culture were maternal in origin. Conclusions: We hope that our protocol for clinical manufacturing of PLMSCs according to GMP standards will assist researchers in isolating MSCs from placental tissue for clinical and pre-clinical applications. Graphical abstract: Harvest method summary of placental tissue. Created with BioRender.com. (Figure presented.) © The Author(s), under exclusive licence to Springer Nature B.V. 2024.
Related Docs
View other Related Docs
1. Standard Operating Procedure for the Good Manufacturing Practice-Compliant Production of Human Endometrial Stem Cells for Multiple Sclerosis, Methods in Molecular Biology (2021)
2. Gmp-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells, Methods in Molecular Biology (2021)
3. Cell Therapy With Placenta-Derived Mesenchymal Stem Cells for Secondary Progressive Multiple Sclerosis Patients in a Phase 1 Clinical Trial, Scientific Reports (2025)
4. Challenges in Mesenchymal Stromal Cell-Based Therapies, Current Stem Cell Research and Therapy (2023)
5. Shining the Light on Clinical Application of Mesenchymal Stem Cell Therapy in Autoimmune Diseases, Stem Cell Research and Therapy (2022)
6. Perspective of Placenta Derived Mesenchymal Stem Cells in Acute Liver Failure, Cell and Bioscience (2020)
7. Placenta Derived Mesenchymal Stem Cells Transplantation in Type 1 Diabetes: Preliminary Report of Phase 1 Clinical Trial, Journal of Diabetes and Metabolic Disorders (2021)
8. Advances in Neurorestoratology—Current Status and Future Developments, International Review of Neurobiology (2023)
Experts (# of related papers)
View all Related Experts
Babak Arjmand (9)
Hamidreza Aghayan (8)
Other Related Docs
9. Clinical Cell Therapy Guidelines for Neurorestoration (Ianr/Canr 2022), Journal of Neurorestoratology (2022)
10. Gmp-Compliant Mesenchymal Stem Cell-Derived Exosomes for Cell-Free Therapy in Cancer, Methods in Molecular Biology (2024)
11. Endometrial and Menstrual Blood Mesenchymal Stem/Stromal Cells: Biological Properties and Clinical Application, Frontiers in Cell and Developmental Biology (2020)
12. The Fingerprints of Biomedical Science in Internal Medicine, Advances in Experimental Medicine and Biology (2022)
13. A Comparative Study of Pathogen Inactivation Technologies in Human Platelet Lysate and Its Optimal Efficiency in Human Placenta-Derived Stem Cells Culture, Journal of Virological Methods (2022)
14. Mesenchymal Stem Cells’ Seeded Amniotic Membrane As a Tissue-Engineered Dressing for Wound Healing, Drug Delivery and Translational Research (2022)
15. Recent Advances in Mesenchymal Stem Cell Therapy for Multiple Sclerosis: Clinical Applications and Challenges, Frontiers in Cell and Developmental Biology (2025)
16. Cell-Based Vaccines: Frontiers in Medical Technology for Cancer Treatment, Regenerative Engineering and Translational Medicine (2024)
17. Current Advances in Stem Cell Therapy in the Treatment of Multiple Sclerosis, Reviews in the Neurosciences (2023)
18. Stem Cell Therapy ‒Approach for Multiple Sclerosis Treatment, Archives of Neuroscience (2016)
19. Human Fetal Skin Fibroblast Isolation and Expansion for Clinical Application, Methods in Molecular Biology (2020)
20. A Focus on Allogeneic Mesenchymal Stromal Cells As a Versatile Therapeutic Tool for Treating Multiple Sclerosis, Stem Cell Research and Therapy (2021)
21. Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis, Current Stem Cell Research and Therapy (2016)